Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice

NeuroToxicology

Volumn 33, Issue 5, 2012, Pages 1305-1313

  Marusich, Julie A ^a   Grant, Kateland R ^a   Blough, Bruce E ^a   Wiley, Jenny L ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

Locomotor activity; MDPV; Mephedrone; Methylone; Mouse; Synthetic cathinones

Indexed keywords

3 FLUOROMETHCATHINONE; 4 FLUOROMETHCATHINONE; 4' METHYLMETHCATHINONE; BALT SALT; CATHINONE; COCAINE; METHAMPHETAMINE; METHEDRONE; METHYLENEDIOXYPHYROVALERONE; METHYLONE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATAXIA; CONTROLLED STUDY; CONVULSION; EXPERIMENTAL TEST; EXPLORATORY BEHAVIOR; FUNCTIONAL OBSERVATIONAL BATTERY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST;

ALKALOIDS; ANALYSIS OF VARIANCE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HYPOGLYCINS; MALE; METHAMPHETAMINE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; OBSERVATION; PROPIOPHENONES; PSYCHOMOTOR PERFORMANCE; ROTAROD PERFORMANCE TEST; TIME FACTORS;

MUS; MUSCOVY DUCK PARVOVIRUS;

EID: 84867232376     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.08.003     Document Type: Article

References (56)

1. ACMD (Advisory Council on the Misuse of Drugs). Consideration of the cathinones; 2010.
2. al-Meshal I.A., Qureshi S., Ageel A.M., Tariq M. The toxicity of Catha edulis (khat) in mice. J Subst Abuse 1991, 3:107-115.
3. American Association of Poison Control Centers. Bath salts data, Updated January 5, 2012; 2012.
4. Angoa-Pérez M., Kane M.J., Francescutti D.M., Sykes K.E., Shah M.M., Mohammed A.M., et al. Mephedrone, an abused psychoactive component of "bath salts" and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 2012, 120:1097-1107.
5. Antonowicz J.L., Metzger A.K., Ramanujam S.L. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 2011, 33(640):e5-e6.
6. Banjaw M.Y., Mayerhofer A., Schmidt W.J. Anticataleptic activity of cathinone and MDMA (Ecstasy) upon acute and subchronic administration in rat. Synapse 2003, 49:232-238.
7. Banjaw M.Y., Fendt M., Schmidt W.J. Clozapine attenuates the locomotor sensitisation and the prepulse inhibition deficit induced by a repeated oral administration of Catha edulis extract and cathinone in rats. Behav Brain Res 2005, 160:365-373.
8. Banjaw M.Y., Miczek K., Schmidt W.J. Repeated Catha edulis oral administration enhances the baseline aggressive behavior in isolated rats. J Neural Transm 2006, 113:543-556.
9. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
10. Berardelli A., Capocaccia L., Pacitti C., Tancredi V., Quinteri F., Elmi A.S. Behavioral and EEG effects induced by an amphetamine like substance (cathinone) in rats. Pharmacol Res Commun 1980, 12:959-964.
11. Calabrese E.J. Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic dose responses are dominant. Crit Rev Toxicol 2008, 387:599-617.
12. Camilleri A., Johnston M.R., Brennan M., Davis S., Caldicott D.G.E. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluormethamphetamine, α-phthalimidopropiophenone and nethylcathinone. Forens Sci Int 2010, 197:59.
13. CDC (Center for Disease Control) Emergency Department visits after use of a drug sold as "Bath Salts" Morb Mortal Wkly Rep 2011, 60:624-627.
14. Cozzi N.V., Sievert M.K., Shulgin A.T., Jacob P., Ruoho A.E. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 1999, 381:63-69.
15. DEA (Drug Enforcement Agency). Synthetic cathinones - DEA request for information posted 3/31/11; 2011 [retrieved 28.07.11].
16. Eastwood N. Legal eye. Drugs and Alcohol Today 2010, 10:6-9.
17. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). EMCDDA and Europol step up information collection on mephedrone; 2010.
18. Fischman M.W. Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs. NIDA Res Monogr 1989, 92:211-230.
19. Fleckenstein A.E., Gibb J.W., Hanson G. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol. 2000, 406:1-13.
20. Forster M.J., Lal H. Estimating age-related changes in psychomotor function: influence of practice and of level of caloric intake in different genotypes. Neurobiol Aging 1999, 20:167-176.
21. Frith C.H., Chang L.W., Lattin D.L., Walls R.C., Hamm J., Doblin R. Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat. Fundam Appl Toxicol 1987, 9:110-119.
22. Gibbons S., Zloh M. An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett 2010, 20:4135-4139.
23. Griffiths P., Lopez D., Sedefov R., Gallegos A., Hughes B., Noor A., et al. Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol 2010, 132:578-583.
24. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011, 339:530-536.
25. Jatav V., Mishra P., Kashaw S., Stables J.P. CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones. Eur J Med Chem 2008, 43:1945-1954.
26. Kalix P. Cathinone, a natural amphetamine. Pharmacol Toxicol 1992, 70:77-86.
27. Kalix P., Braenden O. Pharmacological aspects of the chewing of khat leaves. Pharmacol Rev 1985, 37:149-164.
28. Karila L., Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 2010, 3:552-559.
29. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., et al. Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 2011, 164:1949-1958.
30. Martinez-Clemente J., Escubedo E., Pubill D., Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 2012, 22:231-236.
31. Matecka D., Rothman R.B., Radesca L., de Costa B.R., Dersch C.M., Partilla J.S., et al. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). J Med Chem 1996, 39:4704-4716.
32. Meltzer P.C., Butler D., Deschamps J.R., Madras B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 2006, 49:1420-1432.
33. Motbey C.P., Hunt G.E., Bown M.T., Artiss S., McGregor I.S. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 2011, PMID: 21995495 [Epub ahead of print].
34. Nagai F., Nonaka R., Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007, 559:132-137.
35. National Research Council Guidelines for the care and use of mammals in neuroscience and behavioral research 2003, National Academies Press, Washington, DC.
36. Pehek E.A., Schechter M.D., Yamamoto B.K. Effects of cathinone and amphetamine on the neurochemistry of dopamine in vivo. Neuropharmacology 1990, 29:1171-1176.
37. Proctor G.B., Carpenter G.H. Regulation of salivary gland function by autonomic nerves. Auton Neurosci 2007, 133:3-18.
38. Psychonaut Research Web Mapping Project, MDPV report, London, UK: Institute of Psychiatry, King's College London; 2009.
39. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39:32-41.
40. Saini T.S., Edwards P.C., Kimmes N.S., Carroll L.R., Shaner J.W., Dowd F.J. Etiology of xerostomia and dental caries among methamphetamine abusers. Oral Health Prev Dent 2005, 3:189-195.
41. Schifano F., Albanese A., Fergus S., Stair J.L., Deluca P., Corazza O., et al. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 2011, 214:593-602.
42. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999, 22:521-527.
43. Spanos L.J., Yamamoto B.K. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 1989, 32:835-840.
44. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 2011, 49:499-505.
45. Steinpreis R.E., Anders K.A., Branda E.M., Kruschel C.K. The effects of atypical antipsychotics and phencyclidine (PCP) on rotorod performance. Pharmacol Biochem Behav 1999, 63:387-394.
46. Striebel J.M., Pierre J.M. Acute psychotic sequelae of "bath salts" Schizophr Res 2011, 113:259-260.
47. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005, 75:406-433.
48. Thomas D.M., Walker P.D., Benjamins J.A., Geddes T.J., Kuhn D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 2004, 311:1-7.
49. U.S. Environmental Protection Agency (U.S. EPA). Guidelines for neurotoxicity risk assessment. Risk assessment forum. Washington, DC: U.S. EPA, 630/R-95/001F; 1998a. Available from: http://www.epa.gov/raf/publications/guidelines-neurotoxicity-risk-assessment.htm.
50. U.S. Environmental Protection Agency (U.S. EPA). Health effects guidelines: neurotoxicity screening battery. Washington, DC: U.S. EPA, EPA 712-C-98-238. OPPTS 870.6200; 1998b. Available from: http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series870.htm.
51. Walsh S.L., Wagner G.C. Motor impairments after methamphetamine-induced neurotoxicity in the rat. J Pharmacol Exp Ther 1992, 263:617-626.
52. Winstock A.R., Marsden J., Mitcheson L. What should be done about mephedrone?. BJM 2010, 340:c1605.
53. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
54. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Rev 1987, 94:469-492.
55. Wohlfarth A., Weinmann W. Bioanalysis of new designer drugs. Bioanalysis 2010, 2:965-979.
56. Zelger J.L., Schorno H.X., Carlini E.A. Behavioural effects of cathinone, an amine obtained from Catha edulis Forsk.: comparisons with amphetamine, norpseudoephedrine, apomorphine and nomifensine. Bull Narc 1980, 32:67-81.